Product Description
Mechanisms of Action: FXa Inhibitor
Novel Mechanism: No
Modality: Small Molecule
Route of Administration: Intravenous
FDA Designation: None *
Approval Status: Not Approved
Approved Countries: None
Approved Indications: None
Known Adverse Events: None
Company: Sanofi
Company Location: PARIS I0 75008
Company CEO: Paul Hudson
Additonal Commercial Interests: None
Clinical Description
Countries in Clinic:
Active Clinical Trial Count:
Highest Development Phases
Phase 3: Acute Coronary Syndrome|Non-ST Elevated Myocardial Infarction|Angina, Stable|Angina, Unstable
Phase 2: Coronary Artery Disease|Acute Coronary Syndrome|Venous Thrombosis|Coronary Thrombosis|Coronary Disease
Phase 1: Other|Kidney Diseases
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
---|---|---|---|---|---|
TAO | P3 |
Completed |
Acute Coronary Syndrome |
2013-05-06 |
|
TAO | P3 |
Completed |
Angina, Unstable|Angina, Stable|Acute Coronary Syndrome|Non-ST Elevated Myocardial Infarction |
2013-05-01 |
|
POP6537 | P1 |
Completed |
Kidney Diseases |
2011-07-01 |
|
POP6207 | P1 |
Completed |
Other |
2011-04-01 |